Cabozantinib is a tyrosine kinase inhibitor (TKI) that exhibits substantial activity against specific myeloid leukemia cell lines with FLT3-internal tandem duplication (ITD) [38] or AML1-ETO/KITmt [29] mutations, including MV4-11, Molm13, and Kasumi-1 cells. This evidence concerns the gene RUNX1 and myeloid leukemia.